# NCT01216644 (NCT01216644)

> 5-FU, Leucovorin, Oxaliplatin and Docetaxel (FLOT) Versus Epirubicin, Cisplatin and 5-FU (ECF) in Patients With Locally Advanced, Resectable Gastric Cancer

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT01216644
- Phase: PHASE2, PHASE3
- Status: COMPLETED
- Sponsor: Krankenhaus Nordwest
- Conditions: Gastric Cancer
- Interventions: 5-Fluorouracil; Leucovorin; Oxaliplatin; Docetaxel; Epirubicin; Cisplatin; 5-fluorouracil
- Enrollment: 716
- Primary outcome: median overall survival

## Commentary we found

- X threads: 37
- Podcasts: 32
- YouTube: 14
- X videos: 1

## Order

Deep, $1,950, price fixed at order: https://www.erudio.com/contact?report=nct01216644

## Free build

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT01216644", "email": "<work email>"}; the inbox owner confirms by the emailed link.